About: Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $144.35 (-0.17%)
PVLA NASDAQ Palvella Therapeutics, Inc
Palvella Therapeutics, Inc share price
Atividade de preço de PVLA
Último preço
$ 144,350
Variação (24h)
-0,25 USD (0,17%)
Volume
162.40K
Volume (média 4 sem.)
-
Abertura
$ 145,47
Variação do dia
$ 140,54 - $ 146,11
Fechamento anterior
$ 144,60
Último negócio
17 Nov, 8:53 pm GMT+0
Atrasado
17 Nov, 8:53 pm GMT+0
PVLA price performance
Atrasado
17 Nov, 8:53 pm GMT+0
PVLA details
quote.marketSignals